121 related articles for article (PubMed ID: 1312854)
1. Lisinopril and nifedipine administration inhibits the ex vivo uptake of [45Ca2+] by platelets from hypertensive diabetic patients.
Gill J; Fonseca V; Dandona P; Jeremy JY
Br J Clin Pharmacol; 1992 Feb; 33(2):161-5. PubMed ID: 1312854
[TBL] [Abstract][Full Text] [Related]
2. Differential changes in alpha- and beta-adrenoceptor linked [45Ca2+] uptake in platelets from patients with anorexia nervosa.
Gill J; DeSouza V; Wakeling A; Dandona P; Jeremy JY
J Clin Endocrinol Metab; 1992 Feb; 74(2):441-6. PubMed ID: 1346146
[TBL] [Abstract][Full Text] [Related]
3. Lisinopril and nifedipine: no acute interaction in normotensives.
Lees KR; Reid JL
Br J Clin Pharmacol; 1988 Mar; 25(3):307-13. PubMed ID: 2833920
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of lisinopril and nifedipine retard in essential hypertension: a double-blind, placebo-controlled trial.
Richardson PJ; Meany TB; Johnston GD; Kondowe G; Grimmer SF; Breckenridge AM
J Cardiovasc Pharmacol; 1987; 10 Suppl 10():S96-8. PubMed ID: 2455154
[TBL] [Abstract][Full Text] [Related]
5. A clinical pharmacological study of nifedipine and lisinopril alone and in combination.
Lees KR; Meredith PA; Reid JL
J Cardiovasc Pharmacol; 1987; 10 Suppl 10():S105-7. PubMed ID: 2455105
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of treatment effects with an angiotensin converting enzyme inhibitor--lisinopril and a calcium blocker--nifedipine retard on urinary albumin excretion in patients with non-complicated essential hypertension].
Widecka K; Celibała R; Czekalski S
Pol Arch Med Wewn; 1995 Feb; 93(2):135-42. PubMed ID: 7479231
[TBL] [Abstract][Full Text] [Related]
7. Adrenoceptor-linked [45Ca2+] uptake in platelets from diabetic rats: a model for human platelets.
Gill J; Thompson CS; Jeremy JY; Mikhailidis DP
Lab Anim; 1994 Apr; 28(2):143-7. PubMed ID: 8035565
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the antihypertensive effect of lisinopril compared with nifedipine in patients with mild to severe essential hypertension.
Eber B; Brussee H; Rotman B; Kramer R; Klein W
Angiology; 1992 Jun; 43(6):482-9. PubMed ID: 1317687
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study.
O'Donnell MJ; Rowe BR; Lawson N; Horton A; Gyde OH; Barnett AH
J Hum Hypertens; 1993 Aug; 7(4):333-9. PubMed ID: 8410924
[TBL] [Abstract][Full Text] [Related]
10. A single (investigator)-blind randomised control trial comparing the effects of quinapril and nifedipine on platelet function in patients with mild to moderate hypertension.
Islim IF; Bareford D; Beevers DG
Platelets; 2001 Aug; 12(5):274-8. PubMed ID: 11487379
[TBL] [Abstract][Full Text] [Related]
11. Lisinopril in essential hypertension: a six month comparative study with nifedipine.
Richardson PJ; Meany B; Breckenridge AM; Grimmer SF; Johnston GD; Kondowe G
J Hum Hypertens; 1987 Dec; 1(3):175-9. PubMed ID: 2852252
[TBL] [Abstract][Full Text] [Related]
12. Differential alterations of spontaneous and stimulated 45Ca(2+) uptake by platelets from patients with type I and type II diabetes mellitus.
Gill JK; Fonseca V; Dandona P; Mikhailidis DP; Angelini GD; Jeremy JY
J Diabetes Complications; 1999; 13(5-6):271-6. PubMed ID: 10765001
[TBL] [Abstract][Full Text] [Related]
13. Lisinopril: a new angiotensin-converting enzyme inhibitor.
Armayor GM; Lopez LM
Drug Intell Clin Pharm; 1988 May; 22(5):365-72. PubMed ID: 2839326
[TBL] [Abstract][Full Text] [Related]
14. Comparative trial of lisinopril and nifedipine in mild to severe essential hypertension.
Mörlin C; Baglivo H; Boeijinga JK; Breckenridge AM; Clement D; Johnston GD; Klein W; Kramer R; Luccioni R; Meurer KA
J Cardiovasc Pharmacol; 1987; 9 Suppl 3():S49-52. PubMed ID: 2442552
[TBL] [Abstract][Full Text] [Related]
15. Oxidation of low-density lipoprotein in normotensive type 2 diabetic patients. Comparative effects of enalapril versus nifedipine: a randomized cross-over over study.
Rachmani R; Lidar M; Brosh D; Levi Z; Ravid M
Diabetes Res Clin Pract; 2000 May; 48(2):139-45. PubMed ID: 10802151
[TBL] [Abstract][Full Text] [Related]
16. Regulation of sodium excretion in human hypertension: long-term effects of calcium antagonist and angiotensin converting enzyme inhibitor.
Coruzzi P; Musiari L; Mossini GL; Novarini A
J Cardiovasc Pharmacol; 1993 Jun; 21(6):920-5. PubMed ID: 7687717
[TBL] [Abstract][Full Text] [Related]
17. Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.
Lancaster SG; Todd PA
Drugs; 1988 Jun; 35(6):646-69. PubMed ID: 2844497
[TBL] [Abstract][Full Text] [Related]
18. Lisinopril versus slow-release nifedipine in the treatment of mild to moderate hypertension: a multicentre study. The Cooperative Study Group.
Witchitz S; Serradimigni A
J Hum Hypertens; 1989 Jun; 3 Suppl 1():29-33. PubMed ID: 2550643
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients.
Chan JC; Ko GT; Leung DH; Cheung RC; Cheung MY; So WY; Swaminathan R; Nicholls MG; Critchley JA; Cockram CS
Kidney Int; 2000 Feb; 57(2):590-600. PubMed ID: 10652036
[TBL] [Abstract][Full Text] [Related]
20. Lisinopril: a new angiotensin-converting enzyme inhibitor.
Chase SL; Sutton JD
Pharmacotherapy; 1989; 9(3):120-8; discussion 128-30. PubMed ID: 2547199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
